Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s focus on psychedelics, how he got involved with Tryp and what opportunities the company sees in the psychedelics space. “It’s really simple. There are a lot of naturally derived chemistries around that eventually find their way into more traditional drug development pathways. Psychedelics are some of those,” McKee said. “These chemistries have been around since the 1960s and ‘70s. We know they are well tolerated. Since then, several respected academics at NYU, Johns Hopkins, Yale University and others have been studying these compounds.”
In addition, Tryp Therapeutics today announced that it will present at the Canaccord Genuity Virtual Growth Conference. The event is slated to take place virtually on Aug, 10-12, 2021. Beginning at 3:00 p.m. ET on Aug. 10, McKee will provide an overview of the business and its pipeline, including Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program for chronic pain and eating disorder indications. Interested parties should visit https://ibn.fm/uWnDZ to register.
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain chronic pain and eating disorder indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.